ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0926

Risk Factors for Fractures and Osteoporosis Among Patients with Systemic Sclerosis in a United States Cohort

Sina Famenini1, Jamie Perin2, Kristin Wipfler3, Kaleb Michaud4 and Zsuzsanna McMahan5, 1Johns Hopkins School of Medicine, Baltimore, MD, 2JHUSPH, Baltimore, 3FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5Johns Hopkins University, Baltimore

Meeting: ACR Convergence 2020

Keywords: Disability, Fracture, Osteoarthritis, osteoporosis, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Systemic sclerosis (SSc) is associated with several risk factors for osteoporosis and fractures due to malabsorption or malnutrition, physical disability, chronic inflammation, and use of corticosteroid therapy. However, the risks for osteoporosis and fracture in SSc patients in the United States not well-defined. The aim of this study was to examine the relationship between risk factors (e.g. medication use, clinical characteristics of SSc) and the incidence of fractures and osteoporosis (OP) in SSc patients in a large U.S. cohort.

Methods:

Patients from 1998 to 2019 in FORWARD, National Databank for Rheumatic Diseases, were screened. Patients with SSc and respective 5:1 age- and gender-matched patients with osteoarthritis (OA) from the same database were included as controls. The primary endpoint was the occurrence of a physician-confirmed diagnosis of OP or an osteoporotic fracture. Single and multivariate Cox proportional hazard models were used to investigate the risk factors for fractures or OP in the SSc and OA cohorts. Models were constructed using stepwise and purposeful selection methods.

Results:

The study included 922 patients, 154 with SSc and 768 with OA. For 5046 patient-years (median (IQR) 4.16 (6.2)) of follow-up, 90 patients had either a fracture or incident OP. Univariate analysis (Table 2) showed a significant fracture/OP risk (HR (95% CI)) increase for women (HR 2.49 (1.09 – 5.71)), with being underweight (HR 4.57 (1.56 – 13.4)), higher rheumatic disease comorbidity index (HR 1.10 (1.07 – 1.39)), higher Health Assessment Questionnaire Disability Index (HAQ) (HR 1.60 (1.16 – 2.20)), proton pump inhibitor (PPI) use (HR 1.62 (1.05 – 2.47)), SSRI use (HR 1.91 (1.15 – 3.18)), and OP medication use (HR 2.08 (1.10 – 3.94).

The adjusted model (Table 3) of the combined cohort showed a significant increase in fracture/OP risk with PPI use (HR 1.58 (1.01 – 2.49)), higher HAQ score (HR 1.48 (1.00 – 2.50)), and with being underweight (HR 5.37 (1.69 – 17.0)). However, in the subgroup analysis of SSc patients, PPI use was associated with lower risk (HR 0.81 (0.29 – 2.29)), with the lower risk being significant for those with the highest cumulative omeprazole-equivalent PPI exposure (HR 0.15 (0.03 – 0.85).

Conclusion:

Our findings suggest that several risk factors are associated with a higher risk of fractures in SSc. Functional status of SSc and OA patients, as measured by HAQ, is a particularly strong indicator of future fracture/OP risk. Thus, interventions aimed at improving patients’ functional status may lead to improved clinical outcomes. Furthermore, while PPIs are often associated with a higher risk of fractures/OP, our findings suggest that such risks may vary across different disease types. Further investigations are necessary to further characterize these relationships.

Table 1 – Baseline characteristic of patients with Systemic Sclerosis and Osteoarthritis

Table 2. Univariate Risk Factor Analysis of Fractures and Osteoporosis (OP) in Patients with SSc and OA

Table 3. Multivariate Risk Factor Analysis of Fractures and Osteoporosis (OP) in Patients with SSc and OA


Disclosure: S. Famenini, None; J. Perin, None; K. Wipfler, None; K. Michaud, Rheumatology Research Foundation, 2; Z. McMahan, None.

To cite this abstract in AMA style:

Famenini S, Perin J, Wipfler K, Michaud K, McMahan Z. Risk Factors for Fractures and Osteoporosis Among Patients with Systemic Sclerosis in a United States Cohort [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/risk-factors-for-fractures-and-osteoporosis-among-patients-with-systemic-sclerosis-in-a-united-states-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-fractures-and-osteoporosis-among-patients-with-systemic-sclerosis-in-a-united-states-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology